A regulatory requirement non-interventional study to monitor the safety and effectiveness of Jardiance® (empagliflozin, 10mg) in Korean patients with chronic heart failure (NYHA class II-IV)

09/12/2021
02/07/2025
EU PAS number:
EUPAS44641
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

1245-0276-hfref-nis-protocol_v3.0_Redacted.pdf

English (438.35 KB - PDF) View document
Updated protocol

1245-0276-hfref-nis-protocol_v8.0_Redacted

First published: 28/02/2025
English (825.71 KB - PDF) View document
Study results
Study report
Other information